An interventional study of SBRT in Liver Cancer and Liver Metastases, sponsored by Centre Oscar Lambret. Active, not recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Centre Oscar Lambret · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.
Among the 93 studies in Liver Neoplasms with a site in France, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2019, is one of 16 with no phase, reaches primary completion later than 14 of the 27 other live ones, and was the 54th registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18–100
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 28 · Phase 3 21
First in 1999; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 47 across 929 interventional studies indexed under Liver Neoplasms.
Median enrollment 129 across the 66 interventional studies, 303 across the 26 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 93 have an industry lead sponsor. The 10 most frequent:
Centre Oscar Lambret is the lead sponsor of 130 studies on the registry; 13 are open to participants now.
Centre Oscar Lambret has 3 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Liver Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03408665Centre Oscar LambretStereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | 2026-12-01 |
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Liver Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to be treated by SBRT and unable to participate in another trial (non eligible patient or non included centers), can be included in this national study, in a prospective way.
Patients will first go through an inclusion check-up consisting of:
Before the beginning of the treatment, a pre-therapeutic check-up is done:
The SBRT treatment is done in 3 to 6 times and no specific SBRT techniques are asked for, the investigator can choose according to the center habits.
After the treatment, a follow-up will be realized at 3, 6, 9, 12, 18, 24, 30 and 36 months and then once a year until the last patient included reach their 36th month of follow-up. The follow-up check-up consists of a clinical exam, biological test, tumor assessment and tolerance assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
Radiation: SBRT
3 sessions at least, up to 6. Neither specifc device is imposed.
SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis
Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.
Time frame: From baseline to 36 months following up.
Estimate the SBRT efficiency in a prospective way, in term of local progression-free survival (L-PFS) for patient treated with SBRT in the 4 considered clinical situations.
Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.
Time frame: From baseline to 36 months following up.
Describe the different SBRT techniques used in the study for liver tumor.
Description of SBRT techniques used.
Time frame: From baseline to 36 months following up.
Determine the SBRT feasibility by comparison of planned SBRT to performed SBRT.
Description of reasons leading to SBRT scheme modification or interruption.
Time frame: From baseline to 36 months following up.
Estimate the SBRT efficiency in a prospective way, in term of overall survival (OS) in the 4 considered clinical situations.
Overall survivall thanks to Kaplan-meier method, from registration date to date of death.
Time frame: From baseline to 36 months following up.
Estimate the SBRT efficiency in a prospective way, in term of progression-free survival (PFS) in the 4 considered clinical situations.
Progression-free survival (PFS) thanks to Kaplan-Meier method from registration date to date of progressive disease.
Time frame: From baseline to 36 months following up.
Assess the immediate and delayed toxicity.
Description of toxicity associated to SBRT or the fiducial use thanks to NCI-CTCAE v4.0.
Time frame: From baseline to 36 months following up.
Estimate the quality-adjusted survival (Q-TWiST) for patients in each of the 4 considered clinical situations.
Q-TWIST consists in 3 clinical states: time in toxicity before progressive disease, time in progressive disease, time without toxicity nor progressive disease.
Time frame: From baseline to 36 months following up.
Estimate the proportion of patients for whom an hospitalization is required.
during the treatment and until 3 months after and the cumulative duration of the hospitalization over those 3 months.
Time frame: From baseline to 36 months following up.
Estimate the impact of the different SBRT techniques on SBRT efficacy according to L-PFS.
Estimation of impact of SBRT technique used on SBRT efficacy according to L-PFS.
Time frame: From baseline to 36 months following up.
Estimate the impact of the different SBRT techniques on SBRT efficacy according to PFS.
Estimation of impact of SBRT technique used on SBRT efficacy according to PFS.
Time frame: From baseline to 36 months following up.
Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.
Estimation of impact of SBRT technique used on SBRT efficacy according to OS.
Time frame: From baseline to 36 months following up.
Quality of life according to QLQ-C30 questionnaire
QLQ-C30 will be filled at baseline, at the 3-months follow-up and at the 6-months follow-up.
Time frame: From Baseline to the 6-months follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 92 months after the start.
Of 149 non-industry interventional studies with no phase under Liver Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 73. This study's planned 92 months is above that.
Counting every sponsor, half of 168 studies reached it within 39 months; a quarter within 18 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.